These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 29949781)

  • 1. Omalizumab in chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response.
    Nettis E; Cegolon L; Di Leo E; Lodi Rizzini F; Detoraki A; Canonica GW;
    Ann Allergy Asthma Immunol; 2018 Oct; 121(4):474-478. PubMed ID: 29949781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.
    Nettis E; Cegolon L; Di Leo E; Canonica WG; Detoraki A;
    Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.
    Kaplan A; Ferrer M; Bernstein JA; Antonova E; Trzaskoma B; Raimundo K; Rosén K; Omachi TA; Khalil S; Zazzali JL
    J Allergy Clin Immunol; 2016 Feb; 137(2):474-81. PubMed ID: 26483177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
    Ghazanfar MN; Holm JG; Thomsen SF
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis.
    Ferrer M; Giménez-Arnau A; Saldana D; Janssens N; Balp MM; Khalil S; Risson V
    J Allergy Clin Immunol Pract; 2018; 6(4):1191-1197.e5. PubMed ID: 29655772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
    Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R
    J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
    Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
    Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
    [No Abstract]   [Full Text] [Related]  

  • 8. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome.
    Jeong SH; Lim DJ; Chang SE; Kim KH; Kim KJ; Park EJ
    J Korean Med Sci; 2022 Jul; 37(27):e211. PubMed ID: 35818702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
    Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
    Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study.
    Hide M; Igarashi A; Yagami A; Chinuki Y; Inomata N; Fukunaga A; Kaiser G; Wang J; Matsushima S; Greenberg S; Khalil S
    Allergol Int; 2018 Apr; 67(2):243-252. PubMed ID: 29102514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
    Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL
    Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.
    Saini SS; Bindslev-Jensen C; Maurer M; Grob JJ; Bülbül Baskan E; Bradley MS; Canvin J; Rahmaoui A; Georgiou P; Alpan O; Spector S; Rosén K
    J Invest Dermatol; 2015 Jan; 135(1):67-75. PubMed ID: 25046337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
    Brás R; Esteves Caldeira L; Bernardino A; Costa C
    Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
    Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
    Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
    [No Abstract]   [Full Text] [Related]  

  • 15. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
    Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
    Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.
    Jain V; Giménez-Arnau A; Hayama K; Reich A; Carr W; Tillinghast J; Dahale S; Lheritier K; Walsh P; Zharkov A; Hugot S; Haemmerle S
    J Allergy Clin Immunol; 2024 Feb; 153(2):479-486.e4. PubMed ID: 37866460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effectiveness of Omalizumab Treatment in Real-Life is Lower in Patients with Chronic Urticaria Longer than 18 Months' Evolution and Prior Immunosuppressive Treatment.
    Cubiró X; Spertino J; Rozas-Muñoz E; Serra-Baldrich E; Puig L
    Actas Dermosifiliogr (Engl Ed); 2019 May; 110(4):289-296. PubMed ID: 30360885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria.
    Kitsioulis NA; Xepapadaki P; Roussaki-Schulze AV; Papadopoulos N; Zafiriou E
    Int Arch Allergy Immunol; 2017; 172(3):161-166. PubMed ID: 28380487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.
    Maurer M; Casale TB; Saini SS; Ben-Shoshan M; Giménez-Arnau AM; Bernstein JA; Yagami A; Stjepanovic A; Radin A; Staudinger HW; Patel N; Amin N; Akinlade B; Fan C; Bauer D; Yancopoulos GD; Patel K; Mannent LP; Laws E
    J Allergy Clin Immunol; 2024 Jul; 154(1):184-194. PubMed ID: 38431226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.
    Altrichter S; Staubach P; Pasha M; Singh B; Chang AT; Bernstein JA; Rasmussen HS; Siebenhaar F; Maurer M
    J Allergy Clin Immunol; 2022 May; 149(5):1683-1690.e7. PubMed ID: 34954198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.